Molecular Partners AGMLLCF 25 Market Cap is $144.68 Mil as of Jun. 24, 2026. GuruFocus rates MLLCF with a GF Score™ of 25/100 and a GF Value™ of $0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 1,430 Biotechnology companies, Molecular Partners AG ranks better than 53.36% on this metric.
Molecular Partners AG's quarterly market cap
increased
from Sep. 2025 ($130.90 Mil) to Dec. 2025 ($130.94 Mil) but then
declined
from Dec. 2025 ($130.94 Mil) to Mar. 2026 ($84.40 Mil).
Molecular Partners AG's annual market cap
increased
from Dec. 2023 ($141.27 Mil) to Dec. 2024 ($151.51 Mil) but then
declined
from Dec. 2024 ($151.51 Mil) to Dec. 2025 ($130.94 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Molecular Partners AG's Enterprise Value for Today is $50.51 Mil.
Molecular Partners AG (OTCPK:MLLCF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Molecular Partners AG's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Market Cap distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Molecular Partners AG's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Market Cap of $144.68 Mil as of Jun. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Molecular Partners AG and its competitors. According to the industry distribution chart, Molecular Partners AG ranks #667 out of 1430 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Molecular Partners AG's Market Cap too high?
Molecular Partners AG's current Market Cap is $144.68 Mil. The Biotechnology industry median Market Cap is 117.26. Molecular Partners AG's value of $144.68 Mil is 23.4% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #667 out of 1430 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #667 out of 1430 companies for Market Cap. This puts Molecular Partners AG in the upper half of its industry. The industry median Market Cap is 117.26. Molecular Partners AG's value of $144.68 Mil is 23.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.26, based on 1,430 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Market Cap of $144.68 Mil is 23.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Molecular Partners AG and its competitors. For the Biotechnology industry, the median Market Cap is 117.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Market Cap is $144.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Based on GuruFocus' analysis, Molecular Partners AG (MLLCF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.43, compared to a current price of $3.60 — trading 737.2% above its estimated fair value. The current Market Cap is $144.68 Mil and 23.4% above the Biotechnology industry median of 117.26. Molecular Partners AG's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Market Cap is $144.68 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Molecular Partners AG (MLLCF) Overvalued in 2026?
Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued.
The current stock price of $3.60 is trading 737.2% above its estimated GF Value™ of $0.43.
GuruFocus considers Molecular Partners AG to be Significantly Overvalued.
Key valuation signals for MLLCF:
Market Cap: $144.68 Mil
GF Value™: $0.43 vs. price of $3.60 (737.2% above fair value)
Industry Position: 23.4% above the Biotechnology median (#667 of 1430)
No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score
Get the complete analysis for MLLCF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
